TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24899709

Group type: EXPERIMENTAL
Intervention: Resveratrol (200 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 22939758

Group type: EXPERIMENTAL
Intervention: High-dose grass pollen SLIT
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 20303198

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 410

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 410
Study: 18337059

Group type: EXPERIMENTAL
Intervention: Green tea (GT) 2 g of leaves in 200 mL of water, three times per day for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no green tea)
Number of subjects: 14
Study: 16801459

Group type: EXPERIMENTAL
Intervention: Bosentan (n=37)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 54
Study: 14643036

Group type: EXPERIMENTAL
Intervention: Urinary bladder catheterization
Number of subjects: 270

Group type: COMPARATOR
Intervention: No catheterization (Control)
Number of subjects: 270
Study: 10926708

Group type: EXPERIMENTAL
Intervention: Oil-containing lotion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control lotion
Number of subjects: 54
Study: 8828530

Group type: EXPERIMENTAL
Intervention: Montelukast (MK-0476), 200 mg, three times daily for 10 1/3 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1467051

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of left ventricular regional wall motion
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Simultaneous echocardiographic examination
Number of subjects: 66
Study: 6377525

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 micrograms in 8 ml normal saline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pethidine 1.5 mg/kg 4-6-hourly as required
Number of subjects: 31
Study: 30175844

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 29024718

Group type: EXPERIMENTAL
Intervention: Subpleural catheter
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intraoperative incision site injection
Number of subjects: 86
Study: 27291639

Group type: EXPERIMENTAL
Intervention: 5-h nightly sleep opportunity (Sleep Restriction)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 9-h nightly sleep opportunity (Control)
Number of subjects: 56
Study: 24646201

Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pap test reminder letter
Number of subjects: 0
Study: 22456780

Group type: EXPERIMENTAL
Intervention: MEB complexed with chitin nano-crystals (topical emulsion and oral hard capsules)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20068255

Group type: EXPERIMENTAL
Intervention: Early physiotherapy including manual lymph drainage, massage of scar tissue, and progressive active and action assisted shoulder exercises, along with an educational strategy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group receiving only the educational strategy
Number of subjects: 120
Study: 17885011

Group type: EXPERIMENTAL
Intervention: Cava (30 g ethanol/d for 28 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gin (30 g ethanol/d for 28 days)
Number of subjects: 20
Study: 15831802

Group type: EXPERIMENTAL
Intervention: Glu+Caf (48 g/h + 5 mg x kg(‐1) x h(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glu (48 g/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Wat (plain water)
Number of subjects: 8
Study: 11814529

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 10414411

Group type: EXPERIMENTAL
Intervention: Formoterol (6 or 24 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8776078

Group type: EXPERIMENTAL
Intervention: Cycling at 55% VO2max
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cycling at 70% VO2max
Number of subjects: 20

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 20
Study: 2341993

Group type: EXPERIMENTAL
Intervention: In-hospital counselling in addition to routine care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 60
Study: 7322717

Group type: EXPERIMENTAL
Intervention: Phenobarbital (daily for a mean of 35 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No phenobarbital
Number of subjects: 50
Study: 31455305

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Compositional data analysis
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Multiple linear regression
Number of subjects: 841
Study: 28231822

Group type: EXPERIMENTAL
Intervention: Cilostazol (50 mg) twice per day as an add-on therapy combined with AChEIs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not receiving cilostazol)
Number of subjects: 60
Study: 27128214

Group type: EXPERIMENTAL
Intervention: FSK0808
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference filgrastim (Gran(®))
Number of subjects: 0
Study: 24473673

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate (add-on strategy)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Tocilizumab plus placebo (switch strategy)
Number of subjects: 556
Study: 21068025

Group type: EXPERIMENTAL
Intervention: Escalated dose weekly paclitaxel (80 mg/m² initially followed by 100 and 120 mg/m² unless severe toxicity is observed)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard dose weekly paclitaxel (80 mg/m²)
Number of subjects: 90
Study: 19362232

Group type: EXPERIMENTAL
Intervention: Experienced chiropractor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inexperienced chiropractic student
Number of subjects: 50
Study: 17537155

Group type: EXPERIMENTAL
Intervention: Stress SPECT with a low dose of TcTF (296 MBq)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Combined stress and rest SPECT using TlCl (111 MBq)
Number of subjects: 222
Study: 14966079

Group type: EXPERIMENTAL
Intervention: Doctors' perception of patient pressure
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Perceived medical need
Number of subjects: 847

Group type: COMPARATOR
Intervention: Examination
Number of subjects: 847

Group type: COMPARATOR
Intervention: Prescription
Number of subjects: 847

Group type: COMPARATOR
Intervention: Referral
Number of subjects: 847

Group type: COMPARATOR
Intervention: Investigation
Number of subjects: 847
Study: 11452245

Group type: EXPERIMENTAL
Intervention: 250 mg oral clarithromycin twice daily for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 250 mg oral clarithromycin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9639610

Group type: EXPERIMENTAL
Intervention: Operations supported by randomised controlled trials (RCTs)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Self-evident interventions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Non-randomised prospective or retrospective studies
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Operations not supported by substantial evidence
Number of subjects: 49
Study: 8028383

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 2915441

Group type: EXPERIMENTAL
Intervention: Intravenous prochlorperazine edisylate (10 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (2-mL intravenous injection of sterile saline solution)
Number of subjects: 82
Study: 1107772

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg, three times a day for three weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30683076

Group type: EXPERIMENTAL
Intervention: Savings account offer bundled with health services
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Health services alone
Number of subjects: 1800
Study: 27881389

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 25793222

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 40
Study: 23418877

Group type: EXPERIMENTAL
Intervention: ICG:HSA
Number of subjects: 24

Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 24
Study: 21080183

Group type: EXPERIMENTAL
Intervention: Low-frequency NMES (LF-NMES) at 15 Hz
Number of subjects: 17

Group type: COMPARATOR
Intervention: High-frequency NMES (HF-NMES) at 75 Hz
Number of subjects: 17
Study: 19829040

Group type: EXPERIMENTAL
Intervention: Single dartos flap (monolayer group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Double dartos flap (double flap group)
Number of subjects: 77
Study: 16723655

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (test group)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo varnish (control group)
Number of subjects: 334
Study: 15291994

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study: 11473324

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stents (3 stents over 1 year)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (selective pancreatograms, no stent)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stents
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 9626923

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 7
Study: 7909822

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine levels
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Plasma renin activity
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Jugular venous pressure and third heart sound (S3) gallop
Number of subjects: 859
Study: 3586502

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (100 mmol/day for 10 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control conditions (before potassium supplementation)
Number of subjects: 35
Study: 30170011

Group type: EXPERIMENTAL
Intervention: Digital devices
Number of subjects: 215

Group type: COMPARATOR
Intervention: Analog devices
Number of subjects: 215
Study: 25633239

Group type: EXPERIMENTAL
Intervention: Bemfola(®)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gonal‐f(®)
Number of subjects: 32
Study: 25419886

Group type: EXPERIMENTAL
Intervention: Physical activity and mHealth intervention
Number of subjects: 20
Study: 21953326

Group type: EXPERIMENTAL
Intervention: Peer coaching intervention (telephone counseling at least three times over 6 months)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 15
Study: 21609915

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Vasoactive agents (Control)
Number of subjects: 63
Study: 18534636

Group type: EXPERIMENTAL
Intervention: Nutritionally complete liquid meal (1256 kJ)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cognitive behavior and dietary intervention
Number of subjects: 19
Study: 15900367

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (HMG) at a dose rate of 150 IU/day from day 3 of the cycle
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) agonist at a dose rate of 800 microg/day by nasal spray or 500 microg/day subcutaneously in the mid-luteal phase, followed by standard HMG dose after pituitary down regulation
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clomiphene at a dose rate of 100 mg/day from day 3 and HMG from day 6
Number of subjects: 154
Study: 14620319

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% Abbocaine) applied to the right tonsillar fossa
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal saline (0.9%) applied to the left tonsillar fossa (Control)
Number of subjects: 72
Study: 11008912

Group type: EXPERIMENTAL
Intervention: 5 A Day method
Number of subjects: 260

Group type: COMPARATOR
Intervention: Summation method
Number of subjects: 260

Group type: COMPARATOR
Intervention: 24‐h dietary recalls
Number of subjects: 260

Group type: COMPARATOR
Intervention: Food records
Number of subjects: 260
Study: 9066739

Group type: EXPERIMENTAL
Intervention: Excision plus isolated hyperthermic limb perfusion (IHLP) using melphalan at 2 mg/kg body weight (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Excision (control, n = 14)
Number of subjects: 30
Study: 8350327

Group type: EXPERIMENTAL
Intervention: Intramuscular (im) gold plus 3 im injections of 120 mg methylprednisolone acetate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular (im) gold plus placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (glucocorticoid and gold only)
Number of subjects: 40
Study: 3088664

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg twice a day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg twice a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29398672

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 12,000 IU
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 6,000 IU
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 27315415

Group type: EXPERIMENTAL
Intervention: Problem solving program delivered by physical and occupational therapy practitioners, including a structured interview and an education and resource packet.
Number of subjects: 287

Group type: COMPARATOR
Intervention: Resource packet only (Control group).
Number of subjects: 287
Study: 25106493

Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Best alternative care (BAC)
Number of subjects: 78
Study: 23219490

Group type: EXPERIMENTAL
Intervention: Pay Attention! intervention (16 bi-weekly sessions)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 105
Study: 20861424

Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg/mL at 2 mL/h for 24 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline at 2 mL/h for 24 hours
Number of subjects: 38
Study: 18683195

Group type: EXPERIMENTAL
Intervention: Enzogenol plus vitamin C
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vitamin C only
Number of subjects: 42
Study: 16372192

Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (maximum of 50 mg rtPA injected into the ophthalmic artery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conservative treatment (bulbus massage, topical beta-blocker, acetazolamide, acetylsalicylic acid, heparin, isovolemic hemodilution)
Number of subjects: 200
Study: 12781927

Group type: EXPERIMENTAL
Intervention: Personalized form (PF) letter containing generic cancer information
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Personalized tailored (PT) letter containing minimally tailored individualized risk factor information
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1574
Study: 10899723

Group type: EXPERIMENTAL
Intervention: 100 mg clarithromycin (CLA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin (CLA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin (CLA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg clarithromycin (CLA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 15
Study: 8646825

Group type: EXPERIMENTAL
Intervention: Talinolol perfused at varying rates (not specified) over 160 minutes into different parts of the small intestine.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Talinolol perfusion rates lower than 600 micrograms/min.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Talinolol perfusion at higher rates in the distal region compared to the proximal small intestine.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Talinolol oral bioavailability.
Number of subjects: 6
Study: 31333763

Group type: EXPERIMENTAL
Intervention: iPhone level function of the Measure application
Number of subjects: 21

Group type: COMPARATOR
Intervention: Digital inclinometer
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 21
Study: 30030269

Group type: EXPERIMENTAL
Intervention: FR (fludarabine plus rituximab)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: FR + L (fludarabine plus rituximab plus lenalidomide consolidation)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine plus cyclophosphamide and rituximab)
Number of subjects: 342
Study: 26696461

Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization (RSL)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Wire Localization (WL)
Number of subjects: 125
Study: 24529061

Group type: EXPERIMENTAL
Intervention: Tirapazamine and cisplatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cisplatin and 5FU
Number of subjects: 63
Study: 22201185

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (ARS) with 10 consecutive breaths at a plateau pressure of 40 and 20 cm H(2)O PEEP applied immediately before and after OLV.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with tidal volume (VT) of 8 or 6 ml kg(‐1) for TLV and OLV, respectively.
Number of subjects: 40
Study: 18535542

Group type: EXPERIMENTAL
Intervention: 24-hour recalls (24E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Previous day morning interviews (PDM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Social desirability
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comparison of stretches, internal confabulations, and external confabulations
Number of subjects: 60
Study: 17037003

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study: 12969588

Group type: EXPERIMENTAL
Intervention: Hysteroscopic rollerball electrocoagulation (RBE)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Uterine balloon thermal ablation (Thermachoice)
Number of subjects: 139
Study: 10877166

Group type: EXPERIMENTAL
Intervention: 2-day cefixime (8 mg/kg/day given once daily followed by 3 days of placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5-day cefixime
Number of subjects: 36
Study: 9261912

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moment-based estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent methods with repeated measurements
Number of subjects: 0
Study: 8415813

Group type: EXPERIMENTAL
Intervention: Low dose prostaglandin E1 (PGE1) infusion (0.02 microgram kg‐1 min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 20
Study: 3534859

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 to 50 mg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Increasing doses of frusemide (25 to 100 mg o.d.)
Number of subjects: 15
Study: 29730130

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 70
Study: 27254028

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study: 24115138

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Calcium carbonate alone (D‐)
Number of subjects: 150
Study: 23477160

Group type: EXPERIMENTAL
Intervention: Compound Xiatianwu combined with methotrexate (MTX)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups (Compound Xiatianwu + MTX and MTX)
Number of subjects: 104
Study: 19930776

Group type: EXPERIMENTAL
Intervention: Daily mometasone furoate nasal spray for six weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-adjusted regimen of mometasone furoate nasal spray (daily for one week, every alternate day for one week, then self-adjusted for four weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (daily and self-adjusted)
Number of subjects: 60
Study: 18303031

Group type: EXPERIMENTAL
Intervention: CLIP staging system
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: WHO performance status (PS)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: alpha-fetoprotein for BCLC
Number of subjects: 538

Group type: COMPARATOR
Intervention: Okuda staging system
Number of subjects: 538

Group type: COMPARATOR
Intervention: BCLC staging system
Number of subjects: 538
Study: 17000388

Group type: EXPERIMENTAL
Intervention: Tension-free repair (TFR)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Watchful waiting (WW)
Number of subjects: 641
Study: 14603198

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 427
Study: 11452855

Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 86